A 52-year-old woman with dilated cardiomyopathy (EF 28%) and a history of recurrent syncope presents for risk stratification. She is on optimal medical therapy (ACE inhibitor, beta-blocker, aldosterone antagonist). Holter monitoring shows frequent premature ventricular contractions and short runs of non-sustained ventricular tachycardia. Electrolytes and renal function are normal. What is the most appropriate next step in management?

Explanation

## Clinical Context: Primary Prevention in Dilated Cardiomyopathy **Key Point:** This patient meets criteria for primary prevention ICD placement: severely reduced ejection fraction (EF ≤35%), symptomatic arrhythmias (syncope), and non-sustained VT on monitoring despite optimal medical therapy. ## ICD Indications in Cardiomyopathy ```mermaid flowchart TD A[Dilated cardiomyopathy]:::outcome --> B{EF ≤35%?}:::decision B -->|No| C[Optimize medical therapy]:::action B -->|Yes| D{Symptoms or arrhythmias?}:::decision D -->|Syncope/NSVT| E[ICD for primary prevention]:::action D -->|Asymptomatic| F[Consider EPS or ICD]:::decision E --> G[Reduces sudden cardiac death]:::outcome ``` ## Guideline-Based Criteria for ICD | Criterion | Status in This Patient | |-----------|------------------------| | EF ≤35% on optimal medical therapy | ✓ Yes (EF 28%) | | Ischemic or non-ischemic cardiomyopathy | ✓ Non-ischemic (dilated) | | Syncope (marker of arrhythmia risk) | ✓ Yes, recurrent | | NSVT on monitoring | ✓ Yes, documented | | NYHA Class II–III symptoms | Implied by recurrent syncope | **High-Yield:** In non-ischemic cardiomyopathy with EF ≤35%, **syncope + NSVT** is a strong indicator for ICD, even without prior sustained VT or cardiac arrest. ## Why NOT Antiarrhythmic Drugs? **Clinical Pearl:** Amiodarone does NOT reduce mortality in cardiomyopathy and increases toxicity risk with long-term use. The landmark GESICA and CHF-STAT trials showed amiodarone does not prevent sudden death in this population. **Mnemonic:** **CAST Principle** — Class I antiarrhythmics (flecainide, encainide, procainamide) increase mortality in cardiomyopathy. Amiodarone is Class III but also lacks mortality benefit in primary prevention. ## Rationale for Other Options - **Amiodarone:** No mortality benefit in primary prevention; reserved for secondary prevention (post-arrest) or symptomatic arrhythmia suppression. Not first-line for this indication. - **Increase beta-blocker:** Already on optimal medical therapy; further optimization without ICD does not prevent sudden cardiac death in EF ≤35%. - **EPS with ablation:** Ablation of PVCs is not standard for primary prevention in cardiomyopathy. EPS may be considered if ICD is contraindicated, but ICD is the guideline-recommended approach. [cite:Harrison 21e Ch 226; ESC Guidelines on Ventricular Arrhythmias 2019]